These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 34130864)

  • 1. The association between antibiotic use and survival in renal cell carcinoma patients treated with immunotherapy: a multi-center study.
    Guven DC; Acar R; Yekeduz E; Bilgetekin I; Baytemur NK; Erol C; Ceylan F; Sendur MA; Demirci U; Urun Y; Karadurmus N; Erman M; Kilickap S
    Curr Probl Cancer; 2021 Dec; 45(6):100760. PubMed ID: 34130864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer.
    Derosa L; Hellmann MD; Spaziano M; Halpenny D; Fidelle M; Rizvi H; Long N; Plodkowski AJ; Arbour KC; Chaft JE; Rouche JA; Zitvogel L; Zalcman G; Albiges L; Escudier B; Routy B
    Ann Oncol; 2018 Jun; 29(6):1437-1444. PubMed ID: 29617710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. C-reactive protein and neutrophil-lymphocyte ratio are prognostic in metastatic clear-cell renal cell carcinoma patients treated with nivolumab.
    Roussel E; Kinget L; Verbiest A; Debruyne PR; Baldewijns M; Van Poppel H; Albersen M; Beuselinck B
    Urol Oncol; 2021 Apr; 39(4):239.e17-239.e25. PubMed ID: 33485762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adrenal Metastases Are Associated with Poor Outcomes in Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Nivolumab in the GETUG-AFU-26 NIVOREN Phase 2 Trial.
    Billon E; Dalban C; Oudard S; Chevreau C; Laguerre B; Barthélémy P; Borchiellini D; Geoffrois L; Negrier S; Joly F; Thiery-Vuillemin A; Gross-Goupil M; Rolland F; Priou F; Mahammedi H; Tantot F; Escudier B; Chabaud S; Albiges L; Gravis G
    Eur Urol Oncol; 2024 Aug; 7(4):742-750. PubMed ID: 37813745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patterns, predictors and subsequent outcomes of disease progression in metastatic renal cell carcinoma patients treated with nivolumab.
    Zahoor H; Barata PC; Jia X; Martin A; Allman KD; Wood LS; Gilligan TD; Grivas P; Ornstein MC; Garcia JA; Rini BI
    J Immunother Cancer; 2018 Oct; 6(1):107. PubMed ID: 30333065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic and predictive factors to nivolumab in patients with metastatic renal cell carcinoma: a single center study.
    Mollica V; Rizzo A; Tassinari E; Giunchi F; Schiavina R; Fiorentino M; Brunocilla E; Ardizzoni A; Massari F
    Anticancer Drugs; 2021 Jan; 32(1):74-81. PubMed ID: 33290315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic Significance of the Controlling Nutritional Status (CONUT) Score in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab after Failure of Prior Tyrosine Kinase Inhibitors.
    Takemura K; Yuasa T; Fujiwara R; Ito M; Suzuki H; Yonese J; Koga F
    J Urol; 2020 Dec; 204(6):1166-1172. PubMed ID: 32567459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic Treatments for Metastatic Renal Cell Carcinoma: 10-Year Experience of Immunotherapy and Targeted Therapy.
    Kim SH; Park WS; Kim SH; Joung JY; Seo HK; Lee KH; Chung J
    Cancer Res Treat; 2016 Jul; 48(3):1092-101. PubMed ID: 26875203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of Axitinib After Nivolumab Failure in Metastatic Renal Cell Carcinoma.
    Ishihara H; Takagi T; Kondo T; Fukuda H; Tachibana H; Yoshida K; Iizuka J; Okumi M; Ishida H; Tanabe K
    In Vivo; 2020; 34(3):1541-1546. PubMed ID: 32354960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab.
    De Giorgi U; Procopio G; Giannarelli D; Sabbatini R; Bearz A; Buti S; Basso U; Mitterer M; Ortega C; Bidoli P; Ferraù F; Crinò L; Frassoldati A; Marchetti P; Mini E; Scoppola A; Verusio C; Fornarini G; Cartenì G; Caserta C; Sternberg CN
    Clin Cancer Res; 2019 Jul; 25(13):3839-3846. PubMed ID: 30967420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of immunotherapy time-of-day infusion on survival and immunologic correlates in patients with metastatic renal cell carcinoma: a multicenter cohort analysis.
    Patel JS; Woo Y; Draper A; Jansen CS; Carlisle JW; Innominato PF; Lévi FA; Dhabaan L; Master VA; Bilen MA; Khan MK; Lowe MC; Kissick H; Buchwald ZS; Qian DC
    J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38531662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma.
    Auvray M; Auclin E; Barthelemy P; Bono P; Kellokumpu-Lehtinen P; Gross-Goupil M; De Velasco G; Powles T; Mouillet G; Vano YA; Gravis G; Mourey L; Priou F; Rolland F; Escudier B; Albiges L
    Eur J Cancer; 2019 Feb; 108():33-40. PubMed ID: 30616146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Antibiotic Use on Outcomes with Systemic Therapies in Metastatic Renal Cell Carcinoma.
    Lalani AA; Xie W; Braun DA; Kaymakcalan M; Bossé D; Steinharter JA; Martini DJ; Simantov R; Lin X; Wei XX; McGregor BA; McKay RR; Harshman LC; Choueiri TK
    Eur Urol Oncol; 2020 Jun; 3(3):372-381. PubMed ID: 31562048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sodium levels and immunotherapy efficacy in mRCC patients with bone metastases: sub analysis of Meet-Uro 15 study.
    Catalano M; Rebuzzi SE; Maruzzo M; De Giorgi U; Buti S; Galli L; Fornarini G; Zucali PA; Claps M; Chiellino S; Zampiva I; Pipitone S; Ricotta R; Sorarù M; Mollica V; Tudini M; Fratino L; Prati V; Caffo O; Atzori F; Morelli F; Prati G; Nolè F; Vignani F; Cavo A; Di Napoli M; Malgeri A; Naglieri E; Signori A; Banna GL; Rescigno P; Cerbone L; Antonuzzo L; Roviello G
    Front Immunol; 2024; 15():1361010. PubMed ID: 39034992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Yip SM; Wells C; Moreira R; Wong A; Srinivas S; Beuselinck B; Porta C; Sim HW; Ernst DS; Rini BI; Yuasa T; Basappa NS; Kanesvaran R; Wood LA; Canil C; Kapoor A; Fu SYF; Choueiri TK; Heng DYC
    Cancer; 2018 Sep; 124(18):3677-3683. PubMed ID: 30307610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overt Thyroid Dysfunction and Anti-Thyroid Antibodies Predict Response to Anti-PD-1 Immunotherapy in Cancer Patients.
    Basak EA; van der Meer JWM; Hurkmans DP; Schreurs MWJ; Oomen-de Hoop E; van der Veldt AAM; Bins S; Joosse A; Koolen SLW; Debets R; Peeters RP; Aerts JGJV; Mathijssen RHJ; Medici M
    Thyroid; 2020 Jul; 30(7):966-973. PubMed ID: 32151195
    [No Abstract]   [Full Text] [Related]  

  • 17. A Multi-institutional, Retrospective Analysis of Patients with Metastatic Renal Cell Carcinoma to Bone Treated with Combination Ipilimumab and Nivolumab.
    Desai K; Brown L; Wei W; Tucker M; Kao C; Kinsey E; Rini B; Beckermann K; Zhang T; Ornstein MC
    Target Oncol; 2021 Sep; 16(5):633-642. PubMed ID: 34379283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation between the magnitude of best tumor response and patient survival in nivolumab therapy for metastatic renal cell carcinoma.
    Ishihara H; Takagi T; Kondo T; Tachibana H; Fukuda H; Yoshida K; Iizuka J; Kobayashi H; Okumi M; Ishida H; Tanabe K
    Med Oncol; 2019 Mar; 36(4):35. PubMed ID: 30879157
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world outcomes of nivolumab and cabozantinib in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Stukalin I; Wells JC; Graham J; Yuasa T; Beuselinck B; Kollmansberger C; Ernst DS; Agarwal N; Le T; Donskov F; Hansen AR; Bjarnason GA; Srinivas S; Wood LA; Alva AS; Kanesvaran R; Fu SYF; Davis ID; Choueiri TK; Heng DYC
    Curr Oncol; 2019 Apr; 26(2):e175-e179. PubMed ID: 31043824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A red blood cell-based score in the prognostication of patients with metastatic RCC of the Meet-URO 15 study.
    Anpalakhan S; Banna GL; Rebuzzi SE; Fornarini G; Maruzzo M; Zucali PA; Catalano F; Antonj L; Tudini M; Fratino L; Malgeri A; Rescigno P; Signori A; Acunzo A; Silini EM; Mazzaschi G; Buti S
    Immunotherapy; 2024; 16(14-15):963-973. PubMed ID: 39105621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.